- Home
- OMH vs APVO Comparison
OMH vs APVO Comparison
Compare OMH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- APVO
- Stock Information
- Founded
- OMH 2015
- APVO 2016
- Country
- OMH Singapore
- APVO United States
- Employees
- OMH N/A
- APVO N/A
- Industry
- OMH Real Estate
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- APVO Health Care
- Exchange
- OMH Nasdaq
- APVO Nasdaq
- Market Cap
- OMH 25.2M
- APVO 21.7M
- IPO Year
- OMH 2023
- APVO N/A
- Fundamental
- Price
- OMH $0.84
- APVO $1.09
- Analyst Decision
- OMH Hold
- APVO
- Analyst Count
- OMH 1
- APVO 0
- Target Price
- OMH N/A
- APVO N/A
- AVG Volume (30 Days)
- OMH 174.2K
- APVO 757.7K
- Earning Date
- OMH 10-30-2025
- APVO 11-06-2025
- Dividend Yield
- OMH N/A
- APVO N/A
- EPS Growth
- OMH N/A
- APVO N/A
- EPS
- OMH N/A
- APVO N/A
- Revenue
- OMH $7,976,578.00
- APVO N/A
- Revenue This Year
- OMH $28.40
- APVO N/A
- Revenue Next Year
- OMH $23.07
- APVO N/A
- P/E Ratio
- OMH N/A
- APVO N/A
- Revenue Growth
- OMH 117.53
- APVO N/A
- 52 Week Low
- OMH $0.59
- APVO $1.07
- 52 Week High
- OMH $5.10
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- OMH 23.06
- APVO 27.92
- Support Level
- OMH $0.79
- APVO $1.39
- Resistance Level
- OMH $1.57
- APVO $1.54
- Average True Range (ATR)
- OMH 0.10
- APVO 0.09
- MACD
- OMH -0.04
- APVO -0.03
- Stochastic Oscillator
- OMH 6.28
- APVO 3.06
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.